EUVIMEDEUVIMED entdecken
Crossref

L26/P-441 Pricing and marketing of PGT-A on UK fertility clinics’ websites

M. Perrotta

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Perrotta.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question How do UK fertility clinic websites present PGT-A and communicate its costs to patients? Summary answer UK fertility clinic websites vary in how they present and price PGT-A, with increasing emphasis on outcomes and healthy pregnancy/baby, and limited comparability of costs. What is known already Despite evidence suggesting potential risks or reduced effectiveness, the use of PGT-A has increased sharply in recent years. HFEA data show a rise from 177 PGT-A cycles in 2020 to 1,187 in 2023 (HFEA, 2025). A 2019 analysis of 41 UK clinics advertising PGT-A found that around half claimed improved outcomes, such as higher pregnancy or live birth rates, with prices ranging from £2,100 to £3,295 (average £2,695), although cost components were not specified (van de Wiel et al., 2020). Study design, size, duration The study comprised two stages. Stage 1 (November 2024–January 2025) involved in-depth analysis of how PGT-A was presented on 15 London-based fertility clinic websites, reflecting survey data showing that 56% of respondents who had PGT-A received treatment in London. Stage 2 (February–March 2025) consisted of a systematic analysis of all UK-licensed fertility clinic websites, focusing on the costs associated with PGT-A and identifying 125 unique price lists. Participants/materials, setting, methods The study analysed publicly available materials from UK-licensed fertility clinic websites. Website content from a sample of clinics was systematically collected to examine how PGT-A was marketed, including claims and framing. Pricing data were extracted from collected price lists and analysed for structure, costs, and the clarity and comparability of information across clinics. Main results and the role of chance Website analysis revealed that claims focused primarily on two potential benefits of PGT-A: improving clinical outcomes and offering a “healthy” pregnancy/baby. The latter claims are particularly concerning, as these terms are ambiguously defined, open to multiple interpretations, and could potentially mislead patients. Previous research shows that among individuals choosing PGT-A, 56% cited having a healthy baby as the primary reason, 18% aimed to reduce birth defects, and 16% sought to decrease the risk of miscarriage (Quinn et al., 2018). Risks associated with PGT-A were largely downplayed: only three clinics noted that the test may not be fully accurate, and just two mentioned possible harms, such as reduced treatment effectiveness or the discarding of healthy embryos. Further research on claims is needed to assess whether the London-based sample is representative. Of 125 price lists reviewed, 54 mentioned PGT-A, with most clinics located in England (51). Costs are difficult to compare due to mixed pricing models, which typically include a set-up or biopsy fee (£300–£1,550, mean £1,179) plus a per-embryo testing fee (£295–£500, mean £395). Total costs for four embryos, including counselling, ranged from £1,800 to £3,250 (mean £2,708), excluding additional procedures such as embryo freezing, storage, or ICSI. Limitations, reasons for caution Limitations include the need to verify whether the London-based sample is representative. Website content and price lists are dynamic and may change over time, so findings reflect the data at the time of collection. Wider implications of the findings Findings indicate that patients may be misled about PGT-A benefits and face unclear, unpredictable costs. Clear communication on risks, realistic outcomes, and total potential costs is needed to support informed decision-making. Trial registration number No

Zitieren

APA

Perrotta, M. (2026). L26/P-441 Pricing and marketing of PGT-A on UK fertility clinics’ websites. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.775

Vancouver

Perrotta M. L26/P-441 Pricing and marketing of PGT-A on UK fertility clinics’ websites. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.775

BibTeX
@article{Perrotta2026,
  author = {Perrotta, M.},
  title = {L26/P-441 Pricing and marketing of PGT-A on UK fertility clinics’ websites},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.775}
}
Kostenlos starten →